AN2 Therapeutics Announces Results From Two Studies Evaluating Its Oral CPSF3 Inhibitor, AN2-502998, For The Treatment Of Chronic Chagas Disease; Parasites Eliminated With 28-Day Treatment In 100% Of Nonhuman Primates

뉴스 본문을 불러오고 있어요.

AN2 Therapeutics Announces Results From Two Studies Evaluating Its Oral CPSF3 Inhibitor, AN2-502998, For The Treatment Of Chronic Chagas Disease; Parasites Eliminated With 28-Day Treatment In 100% Of Nonhuman Primates | 웨이프 WAPE

AN2 Therapeutics Announces Results From Two Studies Evaluating Its Oral CPSF3 Inhibitor, AN2-502998, For The Treatment Of Chronic Chagas Disease; Parasites Eliminated With 28-Day Treatment In 100% Of Nonhuman Primates

기사 요약

관련 종목

댓글 —